, ,

Unlocking Urologic Oncology Innovation QuickFire Challenge

Overview

As our population ages, the incidence of bladder and prostate cancers (commonly known as Genitourinary or GU cancers) continues to increase. Newer, more effective and less-invasive treatment options must be made available to help meet the needs of patients living with these growing diseases.1

Despite recent therapeutic achievements, including systemic immunotherapies, antibody-drug conjugates, and next-generation robotic surgical tools, additional scientific discovery is needed. This unmet medical need is not just a challenge—it is an invitation to innovate, by harnessing the power of cutting-edge research, interdisciplinary collaboration, and bold thinking to potentially reshape the future of Urologic cancer treatment.

As we look to a future where every patient, regardless of their cancer’s complexity, finds an effective treatment, Johnson & Johnson, together with the American Urological Association (AUA), has launched the Unlocking Urologic Oncology Innovation QuickFire Challenge. Innovators from across the globe are invited to submit their transformative potential solutions to improve treatment and care of patients with Bladder and Prostate Cancers.

The innovators with the best idea(s) will have the opportunity to receive grant funding from a total pool of up to $300,000, virtual access to the Johnson & Johnson global incubator network, JLABS, and mentorship from experts across Johnson & Johnson.*

*Subject to terms and conditions of applicable QuickFire Challenge and execution of an award agreement

Why this challenge matters to us

At Johnson & Johnson, we are committed to tackling the most critical healthcare challenges to improve patient care. Within the Genitourinary space, we recognize that Bladder and Prostate Cancers are impacting patients disproportionately.1

Building on our commitment to championing transformative innovation and our legacy of engagement with the American Urological Association, including as a founding member of the AUA Clinical Trial Consortium (AUACTC) and AUA Innovation Nexus Founders’ Circle advisory board, this QuickFire Challenge is an opportunity to support the next generation of innovation in urology.

1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992434/

What we’re looking for

Innovators from across the globe are invited to submit transformative potential solutions to help improve treatment and care of patients with Bladder and Prostate Cancers. Specific areas of interest include:

Therapeutics:

Surgery:

Criteria

Potential solutions will be evaluated by a panel of reviewers on their ability to meet the following criteria:

Awards

The innovators with the best idea(s) will have the opportunity to receive grant funding from a total pool of up to $300,000, virtual access to the Johnson & Johnson global incubator network, JLABS, and mentorship from experts across Johnson & Johnson.

Timeline

About Johnson & Johnson

Johnson & Johnson works across the innovative medicine and medical technology sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists, and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.

More Articles from the Medical Industry

Unlocking Urologic Oncology Innovation QuickFire Challenge

Overview As our population ages, the incidence of bladder and prostate cancers (commonly known as Genitourinary or GU cancers) continues …

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control

QIAcuity digital PCR kits, assays and protocols for lentivirus-based therapies support quality control in cell and gene therapy manufacturing Expansion …

5 facts about Analitika Expo 2025

Find out the most interesting facts about the upcoming exhibition and get a free ticket with a special promo code …

BIOTRONIK and Egg Medical Form Strategic Alliance to Improve Radiation Protection for Interventional Healthcare Workers

BIOTRONIK, a global leader in cardiovascular, endovascular, and neuromodulation solutions, today announced it is partnering with Egg Medical, Inc., a …
Share via
Copy link